Health Care & Life Sciences » Biotechnology | Heat Biologics Inc.

Heat Biologics Inc.

Heat Biologics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.76
Market Cap
$23.51 M
Shares Outstanding
34.07 M
Public Float
29.66 M

Profile

Address
801 Capitola Drive
Durham North Carolina 27713
United States
Employees -
Website http://www.heatbio.com
Updated 07/08/2019
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.

Financials

View All
Created with Highcharts 5.0.14Heat Biologics Inc.Net Income. Fiscal year is January-December. All values USD Thousands.8 7118 71111 78811 78820 29520 29512 57412 57411 84111 84115 73315 73320132014201520162017201805k10k15k20k25k
Created with Highcharts 5.0.14Heat Biologics Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.0000003413411 5191 5195 7935 79320132014201520162017201801k2k3k4k5k6k7k

Jeff A. Wolf
Chairman, President & Chief Executive Officer
John James Monahan
Independent Director